David M Margolis MD
HIV/AIDS Medicine
Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Join to View Full Profile
101 Manning DrChapel Hill, NC 27599
Phone+1 984-974-7198
Dr. Margolis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Margolis, based in Chapel Hill, NC, specializes in Infectious Disease with a subspeciality in HIV/AIDS Medicine. His extensive education includes a residency in Internal Medicine at Tufts Medical Center, a fellowship in Infectious Disease at National Institutes of Health Clinical Center, and an MD from Tufts University School of Medicine. He currently serves as the Professor of Medicine, Microbiology & Immunology, Epidemiology Director at the UNC HIV Cure Center and has held positions at University of Texas, Dallas Veterans Center and University of Maryland. As a prolific contributor to his field, he has a number of publications and has led multiple clinical trials. His work has been recognized with honors from organizations like the Association of American Physicians and the American Society for Clinical Investigation.
Education & Training
University of Massachusetts Medical SchoolPost-Doctoral Fellowship, 1991 - 1994
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1988 - 1991
Tufts Medical CenterResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985
Certifications & Licensure
NC State Medical License 2005 - 2026
TX State Medical License 2001 - 2006
MD State Medical License 1989 - 2001
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Fellow AAAS, 2022
- Elected Member Association of American Physicians, 2019
- Elected Member The American Society for Clinical Investigation, 2005
Clinical Trials
Publications & Presentations
PubMed
- Single-cell characterization of the gastrointestinal HIV reservoir reveals heterogeneous cellular phenotypes.Jackson J Peterson, Shipra Chandel, Katherine James, Elizabeth S Bennett, Vincent Wu
The Journal of Clinical Investigation. 2026-02-16 - Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.David Margolis, Michael Watkins, Yali Zhu
Antimicrobial Agents and Chemotherapy. 2025-06-04 - Dolutegravir/Abacavir/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1.Cynthia L Gay, Jessica Keys, JoAnn D Kuruc, Alexis Sponaugle, Kara S McGee
Open Forum Infectious Diseases. 2025-05-01
Journal Articles
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical StudiesElizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
Press Mentions
Brii Biosciences Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 SubvariantsJuly 27th, 2022- Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 SubvariantMay 9th, 2022
- Why COVID-19 Cases May Continue to Decline in the United StatesApril 7th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
